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Results: 85 patients who met the selection criteria were analyzed. The 
demographic features were - males 61%; Caucasians - 54%; African 
Americans - 38%; history of pulmonary disorder- 41%; NSCLC- 78%; 
PS- 0,1- 92%; Stage III- 89%. The median dose of TR was 5940 cGy. 
Radiation ﬁelds have been retrospectively assessed in 41 patients to 
date. 9 of the 41 patients (22%) received involved ﬁeld radiation. 53 
patients (63%) received Cisplatin/Etoposide and 20 patients (24%) 
received Carboplatin/Paclitaxel. 75 patients (88%) received concurrent 
therapy. 31 patients (36%) developed RP; 15 (18%) had RTOG grade ≥ 
3 RP. Median time to development of RP was 4.6 months. Rate of RP 
in females and males was 42% vs. 33% (p=0.49). Rate of RP in patients 
with history of pulmonary disorder at baseline was 49% as compared to 
28% in others (p=0.068). 1 year hospitalization rate was 74% and 37% 
in RP and non-RP patients (p=0.0015). For all 85 patients, the median 
overall survival (OS) was 19.5 months (95% CI 16.4 - 23.3). Length of 
OS did not differ signiﬁcantly (p = 0.59) between the 31 patients who 
had RP vs. the 54 patients who had no RP (median OS: 19.3 vs. 18.8 
months, respectively). The median survival of the 15 patients who had 
severe RP was 16.6 months.
Conclusions: The rate of severe RP in these 85 lung cancer patients, 
treated off-protocol with CT and TR, is higher than that reported in 
clinical trials. Despite higher morbidity (i.e., increased hospitalization) 
in patients with RP, survival duration did not differ signiﬁcantly by RP 
status.
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Background: Four larger clinical trials, IALT, NCIC-JBR10, ANITA 
and Japanese UFT trial, have shown signiﬁcant OS advantages with ad-
juvant chemotherapy. Unless vinorelbine plus cisplatin, whether other 
third generation doublet chemotherapy regimen improves survival of 
patients with non-small-cell lung cancer (NSCLC) is not known. We 
aimed to compare the effect of adjuvant docetaxel plus carboplatin 
versus observation on survival in patients with completely resected 
NSCLC.
Methods: 82 patients with stage IB-IIIA NSCLC from 3 centres in 
China were randomly assigned to 75mg/m(2) docetaxel plus AUC=5 
carboplatin (n=43) or to observation (n=39). The primary endpoint was 
disease free survival (DFS). The second endpoint was overall survival, 
response rate in the chemo group and safety. Analysis was by intention 
to treat. This trial was closed early by the EC as adjuvant chemotherapy 
became a standard therapy for resected NSCLC in 2005.
Results: 43 patients in the chemotherapy group and 39 in the observa-
tion group received their assigned treatment. 45 (54.9%) patients had 
stage IB disease, 20 (24.4%) had stage II disease, and 17 (20.7%) had 
stage IIIA disease. Adenocarcinoma accounted for 62.2% (51 cases, 
Tab.1). The median chemotherapy cycles were 3. After a median 
follow-up of 29.5 months (range 3-51), median disease free survival 
time is not reached in the chemotherapy group and 34 months in the 
observation group (p=0.0173). Median overall survival in both groups 
is not reached (Fig.1). 
Conclusion: Adjuvant docetaxel plus carboplatin extends disease free 
survival in patients with completely resected NSCLC.
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Can the patients with locally advanced non-small cell lung 
cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 
30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent 
radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?
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Background: CCRT plus consolidation chemotherapy is a standard 
treatment of LANSCLC. But there is still a great controversy about 
the chemotherapy regimen for CCRT. A group of physician in Korean 
found 20mg/m2 docetaxel plus 20mg/m2 cisplatin, weekly is maximum 
tolerated dose for patients with LANSCLC during 6 weeks of 63Gy 
radiotherapy. The purpose of our trial was to determine whether the 
NSCLC patients after 2-3 cycles of induction chemotherapy can toler-
ate the chemotherapy regimen of 60 mg/m2 T and 60mg/m2, 2 cycles in 
6 weeks radiotherapy, based on toxicity. 
Methods: Previously untreated 9 patients with histological/cytologi-
cally proven Stage III non-small-cell lung cancer were eligible after 
induction chemotherapy for 2-3 cycles. Followed a month later by con-
tinual radiotherapy (62-70Gy in 31-35 fractions, 6-7weeks) delivered 
concurrently with cisplatin and docetaxel. The dosage of level 1 was 
of 56 mg/m2 docetaxel, on day 1 and 28mg/m2 cisplatin, on day 1 and 
day 2, 2 cycles during CCRT. The radiotherapy model was conformal 
radiotherapy or intensity modulated radiotherapy. The dosage of level 
2 was 60 mg/m2 docetaxel, on day 1 and 30 mg/m2 on day 1 and day 2. 
Response rate was evaluated as complete remission (CR), partial remis-
sion (PR), stable disease (SD) and progressive disease (PD). 
Results: Nine patients were enrolled, with median age of 58, (43-70). 
Seven patients were male, 2 female. The ECOG scores of 4 patients 
were 0, and ECOG scores of 5 patients were 1. The loss of weight of 
8 patients was 0%, that of one patient was ≤5% in three months before 
diagnosis. Seven patients were with squamous cell carcinoma, 2 with 
adenocarcinoma. The objective response was as follows: PR 8/9, SD 
1/9. The toxicities were showed in table 1.
Conclusions: The patients with LANSCLC can tolerate 60mg/m2 
docetaxel and 60mg/m2 cisplatin for 2 cycles during concurrent radio-
therapy after 2-3 cycles of induction chemotherapy.
